Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2228 | Nutrition support Wiki | 1.00 |
drug2448 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D016638 | Critical Illness NIH | 0.13 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
Description: solicited/unsolicited local and systemic AEs after vaccination
Measure: Incidence of adverse events Time: Through 48 weeks post vaccinationDescription: Endpoint titer of binding antibody in serum
Measure: Geometric mean titer (GMT) of antigen-specific binding antibody titers Time: Through 48 weeks post vaccinationDescription: T-cell response of antigen-specific interferon - gamma (IFN-γ) secretion in PBMC at each timepoint
Measure: Evaluation of positive response rate of T cell responses induced by GLS-5310 DNA vaccine Time: Through 48 weeks post vaccinationDescription: Plaque-reduction neutralizing titer(PRNT) in serum at each timepoint
Measure: Geometric mean titer (GMT) of neutralizing antibody titers Time: Through 48 weeks post vaccinationDescription: Endpoint titer of binding antibody in serum at each timepoint
Measure: Determine IgG antibody responses after a single dose of vaccine related to treatment arm Time: Through 1 year post vaccinationDescription: Survival rate
Measure: Measure survival rate of animals administered immune serum from vaccinated individuals and later challenged with SARS-CoV-2. Time: Through 1 year post vaccinationDescription: Endpoint titer of binding antibody in serum at each timepoint Plaque-reduction neutralizing titer in serum at each timepoint T-cell response of antigen-specific interferon - gamma (IFN-γ) secretion in PBMC at each timepoint
Measure: Persistence of immune responses following vaccination with GLS-5310 Time: Through 1 year post vaccinationDescription: Change from baseline in binding antibody titers Change from baseline in T-cell response of antigen-specific interferon - gamma (IFN-γ) Change from baseline in plaque-reduction neutralizing titer(PRNT) in serum
Measure: Determine the extent of immune boosting for participants who are seropositive at baseline following vaccination with GLS-5310 Time: Through 1 year post vaccinationDescription: viral load measurement of blood and major organs
Measure: Measure viral load in organs, including blood, of animals administered immune serum from vaccinated individuals and later challenged with SARS-CoV-2. Time: Through 1 year post vaccinationDescription: pathological examination of organs
Measure: Perform histologic examination of organs of animals administered immune serum from vaccinated individuals and later challenged with SARS-CoV-2. Time: Through 1 year post vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports